TROPION-Lung01 Study Design and Baseline demographics
A few data from poster presentation
Ifinatamab Deruxtecan (I-DXd; DS-7300) in patients with advanced solid
tumors: Updated clinical and biomarker results from a phase 1/2 study
Manish R. Patel,1,2 Toshihiko Doi,³ Takafumi Koyama, 4 Gerald S. Falchook, 5 Claire Friedman, 6 Sarina A. Piha-Paul, Martin Gutierrez, Mark Awad, Ahmad Mattour, 10 Taroh Satoh, 11
Naoko Okamoto, 12 Jasmeet Singh, 12 Naoto Yoshizuka, 12 Meng Qian, 12 Xiaozhong Qian, 12 Brittany P. Tran, 12 Ololade Dosunmu,² Pengcheng Lu, 2 Melissa L. Johnson²
1Florida Cancer Specialists and Research Institute, Sarasota, FL, USA; 2Sarah Cannon Research Institute, Nashville, TN, USA; ³National Cancer Center Hospital East, Chiba, Japan; 4National Cancer Center Hospital, Tokyo,
Japan; 5Sarah Cannon Research Institute at HealthONE, Denver, CO, USA; 6Memorial Sloan Kettering Cancer Center, New York, NY, USA;
7The University of Texas MD Anderson Cancer Center, Houston, TX, USA; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Dana-Farber Cancer Institute, Boston, MA, USA; 10Henry
Ford Health System, Detroit, MI, USA; 11Osaka University Hospital, Osaka, Japan; 12Daiichi Sankyo, Inc., Basking Ridge, NJ, USA
Daiichi-Sankyo
60
60View entire presentation